This article summarizes the latest Italian Medical Oncology Association (AIOM) guidelines on the management of cancer-related and chemotherapy-related anemia with a particular attention to the use of erythropoiesis-stimulating agents and iron supplementation.
RizzoJDBrouwersMHurleyP, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patient with cancer. J Clin Oncol2010; 28: 4996–5010.
2.
BokemeyerCAaproMSCourdiA, et al. European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer2007; 43: 258–270.
3.
SchrijversDDe SamblanxHRoilaF; ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use. Ann Oncol2010; 21 (Suppl 5): v244–v247.
4.
BohliusJBohlkeKCastelliR, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol2019; 37: 1336–1351.
5.
AaproMBeguinYBokemeyerC, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol2018; 29 (Suppl 4): iv96–iv110.
LudwigHFritzE.Anemia in cancer patients. Semin Oncol1998; 25: 2.
8.
WeissGGoodnoughLT.Anemia of chronic disease. N Engl J Med2005; 352: 1011–1023.
9.
AndrewsNC.Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest2004; 113: 1251–1253.
10.
BeguinY.Erythropoietic agents and iron. In: LudwigH eds. Anaemia in Cancer: ESO Scientific Update, 2nd ed.Amsterdam: Elsevier; 2005: 6; 199.
11.
RazzaghdoustAMofidBPeyghambarlouP. Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy. Support Care Cancer2020; 28: 155–161.
12.
VekemanFBookhartBKWhileJ, et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion2009; 49: 895–902.
13.
BohliusJWilsonJSeidenfeldJ, et al. Recombinant human erythropoietin and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst2006; 98: 708–714.
14.
ToniaTMettlerARobertN, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev2012; 12: CD003407.
15.
MintonOStonePRichardsonA, et al. Drug therapy for the management of cancer-related fatigue [updated in 2010; 7: CD006704]. Cochrane Database Syst Rev2008; 1: CD006704.
16.
BohliusJToniaTNueschE, et al. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. BJC2014; 111: 33–45.
17.
BennettCLSilverSMDjulbegovicB, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA2008; 299: 914–924.
18.
BohliusJSchmidLinKBrillantC, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet2009; 373: 1532–1542.
19.
TonelliMHemmelgarnBReimanT, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ2009; 180: E62–E71.
20.
LudwigHCrawfordJOsterborgA, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alpha in the treatment of patients with chemotherapy-induced-anemia. J Clin Oncol2009; 27: 2838–2847.
21.
GlaspyJCrawfordJVansteenkisteJ, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer2010; 102: 301–315.
22.
HadLandBLongmoreGD.Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J Clin Oncol2009; 25: 4217–4226.
23.
AaproMJelkmannWConstantinescuSN, et al. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer2012; 106: 1249–1258.
24.
BennettCLCournoyerDCarsonKR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from Research on Adverse Drug Events and Reports. Blood2005; 106: 3343–3347.
25.
HedenusMBirgegardG.The role of iron supplementation during epoetin treatment for cancer-related anemia. Med Oncol2009; 26: 105–115.
26.
CanonJLVansteenkisteJBodokyG, et al. Randomized, double blind, active-controlled trial of every-3-week darbepoetin alpha for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst2006; 98: 273–284.
27.
GlaspyJVadhan-RajSPatelR, et al. Randomized comparison of every-2-week darbepoetin alpha and weekly epoetin alpha for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol2006; 24: 2290–2297.
28.
SteensmaDPMolinaRSloanJA, et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol2006; 24: 1079–1089.
29.
WalrafenPVerdierFKadriZ, et al. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood2005; 105: 600–608.
30.
GlaspyJHenryDPatelR, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alpha: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alpha. Eur J Cancer2005; 41: 1140–1149.
31.
MeansRTKrantzSB.Progress in understanding the pathogenesis of the anemia of chronic disease. Blood1992; 80: 1639–1647.
32.
AaproMOsterborgAGascónP, et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol2012; 23: 1954–1962.
33.
HenryDH.Supplemental iron: a key to optimizing the response of cancer related anemia to rHuEpo. Oncologist1998; 3: 275–278.
34.
AuerbachMBallardHTroutJR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open label, randomized trial. J Clin Oncol2004; 22: 1301–1307.
35.
AvniTBieberAGrossmanA, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc2015; 90: 12–23.
36.
PedrazzoliPFarrisADel PreteS, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-induced anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol2008; 26: 1619–1625.
37.
BastitLVandebroekAAltintasS, et al. Randomized, multicenter controlled trial comparing the efficacy and safety of darbepoetin alpha administered every three weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol2008; 26: 1611–1618.
38.
HedenusMBirgegårdGNäsmanP, et al. Addition of intravenous iron to epoetin beta increases haemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia2007; 21: 627–632.
39.
HenryDHDahlNVAuerbachM, et al. Intravenous ferric gluconate improves response to epoetin alpha versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist2007; 12: 231–242.
40.
SteensmaDPSloanJADakhilSR, et al. Phase III, randomized study of effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alpha for patients with chemotherapy-induced anemia. J Clin Oncol2011; 29: 97–105.
41.
Gafter GviliARozen-ZviBVidalL, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: systematic review and meta-analysis of randomized controlled trials. Acta Oncol2013; 52: 18–29.
42.
SzucsTDBlankPRSchwenkglenksM, et al. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia. Oncology2011; 81: 45–49.
43.
ChertowGMMasonPDVaage-NilsenO, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transpl2004; 19: 1571–1575.
44.
AuerbachMBallardHGlaspyJ.Clinical update: intravenous iron for anaemia. Lancet2007; 369: 1502–1504.
